ISSUE 3/2026

BDMAI BULLETIN

From the Desk of President

Dear Friends,

Sub: Advisory to Members: Coping with Rising Raw Material and Solvent Prices

The prevailing unrest in West Asia has created significant disruptions across industries worldwide, and the Bulk Drug Industry is no exception. The sudden escalation in crude oil prices has severely impacted the solvents and chemical sectors, with many suppliers already increasing their prices by nearly 50–60%. This development has further strained our industry, which is already facing multiple challenges in both domestic and international markets.

As the well-known saying goes, difficult times bring people together. Our industry is presently going through a challenging phase. While BDMAI and other industry associations are making continuous efforts to represent the concerns of the industry before the Government and seek appropriate policy and fiscal support during these difficult times, it is equally important for the industry itself to take prudent and well-considered steps to safeguard its sustainability.

In this context, I sincerely advise manufacturers to carefully review their cost structures and consider revising product prices wherever necessary to reflect the steep increase in raw material and input costs. Such decisions, taken judiciously and in line with prevailing market conditions, may help mitigate the financial stress faced by manufacturers.

I am aware that a significant portion of our industry operates on advance purchase orders, and implementing price revisions for such orders may pose certain challenges. However, the present extraordinary global situation may warrant invoking appropriate contractual provisions, including force majeure or renegotiation clauses, wherever applicable, to address unforeseen cost escalations.

I request all members to consider this advisory in the right spirit and take suitable steps to ensure that our industry navigates these challenging times with resilience and collective responsibility.

With best regards

Ch. A P Rameswara Rao
National President

In this Bulletin you can expect

GLOBAL PHARMA NEWS

New Drug Developments

Bioxytran reports rapid viral clearance in phase 2 trial

Bioxytran has reported positive results from its completed phase 2 trial of ProLectin-M, showing rapid and sustained viral clearance in subjects with laboratory-confirmed acute viral infection. The company said the study demonstrated complete elimination of viral load in all treated patients by day seven, compared with placebo

Pharma Times 11.2.2026
Read more

RNA-targeting small molecules: a new frontier of drug discovery

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances. While small molecules have long been the cornerstone of the pharmaceutical industry, there is increasingly a demand for innovative precision approaches, often synonymous with biologic therapies. Yet a quiet resurgence in the small molecule sector is building momentum, with its sights set on what was previously considered an “undruggable” target—human RNA.

Pharmaceutical Technology 16.2.2026
Read More

Tremfya data show sustained remission in ulcerative colitis through 3 years

QUASAR long-term extension results highlight durable clinical and endoscopic outcomes - Johnson & Johnson has reported new long-term results from the QUASAR long-term extension study, showing that Tremfya (guselkumab) sustained clinical, endoscopic and histologic outcomes through week 140 in adults with moderately to severely active ulcerative colitis who had not responded adequately to conventional or biologic therapy.

Pharma Times 23.2.2026
Read More

ACD440 granted orphan drug status in the EU

Erythromelalgia treatment gains regulatory support following EMA decision - AlzeCure Pharma has announced that the European Medicines Agency has granted orphan drug status to ACD440, its clinical-stage pain treatment being developed for rythromelalgia. The company, which focuses on diseases affecting the nervous system including Alzheimer’s disease and pain, said the designation strengthens the prospects for advancing ACD440 as a potential therapy for patients with this rare and debilitating condition

Pharma Times 24.2.2026
Read More

GLOBAL PHARMA NEWS

ViiV Healthcare data show lower rates of steatotic liver disease after switching to Dovato

PASO DOBLE sub-analysis indicates metabolic differences between 2-drug and 3-drug HIV regimens - ViiV Healthcare has announced new 96-week findings from a sub-group analysis of the PASO DOBLE study, showing that adults living with HIV-1 who switched to Dovato experienced a lower proportion of steatotic liver disease compared with those switching to Biktarvy. The analysis, presented at the Conference on Retroviruses and Opportunistic Infections 2026, evaluated virologically suppressed adults taking either the 2-drug regimen dolutegravir/lamivudine or the 3-drug regimen bictegravir/emtricitabine/tenofovir alafenamide.

Pharma Times 24.2.2026
Read More

Verdiva Bio completes enrolment for phase 2b study of oral GLP-1 candidate VRB-101

Verdiva Bio has completed enrolment for its phase 2b EVOLVE-2 clinical study of VRB-101, a once-weekly oral GLP-1 peptide analog being developed for body-weight reduction in people with overweight or obesity. The clinical-stage biopharmaceutical company, which focuses on therapies for obesity and cardiometabolic disorders, said more than 200 participants have been enrolled across 22 US sites.Topline results are expected by the end of 2026.

Pharma Times 25.2.2026
Read More

SolasCure trial shows faster healing with Aurase Wound Gel

SolasCure has completed its second phase 2 clinical trial of Aurase Wound Gel, reporting results that indicate substantially faster healing in patients with chronic venous leg ulcers. The company said the CLEANVLU2 study provides clinical validation that the investigational treatment can deliver continuous enzymatic debridement while also activating wound healing. Aurase Wound Gel combines a proprietary hydrogel with the active pharmaceutical ingredient tarumase. CLEANVLU2 followed the earlier phase 2a CLEANVLU1 study, which established proof of concept and showed a strong safety profile and pain-free application. The new trial evaluated efficacy and dose response in patients with treatment-resistant venous leg ulcers

Pharma Times 26.2.2026
Read More

MOUs / Joint Ventures

Mexico enlists Moderna to boost mRNA supply for respiratory diseases

The Mexican Government has struck a long-term agreement with Moderna that will see the drugmaker help the country boost its vaccine offerings against respiratory diseases. As per the five-year agreement, Moderna will supply its respiratory vaccine portfolio, and transfer its Covid-19 vaccine technology to Mexican pharma company Liomont. The latter part of the deal will allow privately-owned Liomont to produce mRNA-1273, Moderna's vaccine approved for preventing Covid-19. The move starkly contrasts recent activities in the US – the FDA shunned a new mRNA influenza candidate from Moderna on 10 February 2026

Pharmaceutical Technology 11.2.2026
Read More

Madrigal expands MASH pipeline in $4.4bn siRNA licensing deal

Madrigal Pharmaceuticals has inked a deal worth up to $4.4bn with Chinese biotech Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals in a bid to expand offerings in the metabolic dysfunction-associated steatohepatitis (MASH) market. The agreement will see Madrigal pay $60m upfront for the development and commercialisation rights to six of Ribo's preclinical, silent interfering RNA (siRNA)-based MASH therapies, which are designed to silence genes encoding proteins that drive the disease's pathology.

Pharmaceutical Technology 12.2.2026
Read More

ArkBio Wins U.S. Clearance for IPF Drug Trial

China-based biotech developer Shanghai Ark Biopharmaceutical Co., Ltd. has received clearance from the U.S. Food and Drug Administration to begin a U.S. clinical study of its experimental anti-fibrotic therapy AK3280 for idiopathic pulmonary fibrosis (IPF).

The agency accepted the company's investigational new drug application, allowing a Phase 2 proof-of-concept trial to proceed. The planned study will be a multi-center, randomized, partially double-blind trial comparing the oral drug against both placebo and an active control. Researchers will evaluate efficacy, safety and pharmacokinetics in patients diagnosed with IPF, a progressive and often fatal lung disease marked by scarring of lung tissue and declining respiratory function

Pharma Journalist 13.2.2026
Read More

GLOBAL PHARMA NEWS

Eli Lilly builds orforglipron cache to avoid previous GLP-1RA shortages

Lilly's amassing of a $1.5bn pre-launch inventory follows sizeable investments into US manufacturing facilities. In a bid to avoid previous shortages of injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs), Eli Lilly has already started to assemble a stockpile of its oral weight loss drug orforglipron. In its 2025 annual report, published in February 2026, Eli Lilly said it has pre-launch inventory capitalised at $1.5bn, most of which is related to orforglipron

Pharmaceutical Technology 16.2.2026
Read More

Teijin, Aska Partner on Gynecology Drug Discovery

Teijin Pharma Limited has signed a joint research agreement with Aska Pharmaceutical Co., Ltd. to develop new small-molecule drug candidates for gynecological diseases, marking a strategic collaboration aimed at accelerating early-stage drug discovery in women's healthcare. The partnership brings together complementary strengths: Teijin Pharma's advanced computational drug design technologies and Aska Pharmaceutical's long-standing clinical expertise in obstetrics and gynecology. Both companies said the goal is to identify innovative therapies that address unmet medical needs affecting women across different stages of life.

Pharma Journalist 16.2.2026
Read More

GSK backs siRNA modality through $1bn Frontier deal

GSK has doubled down on its belief in the silent interfering RNA (siRNA) modality by inking a licensing agreement worth up to just over $1bn with Chinese company, Frontier Biotechnologies. Through this deal, GSK will hand over $40m upfront, as well as up to $963m in development, regulatory and commercial milestone payments in exchange for two of Frontier's early-stage siRNA candidates. This includes a preclinical asset and an Investigational New Drug (IND)-enabled candidate – both of which are being developed to treat kidney diseases driven by inflammation.

Pharmaceutical Technology 24.2.2026
Read More

Boehringer inks $500m Sitryx deal, secures CPNV-driven Hernexeos approval

Boehringer Ingelheim has revamped its portfolio and pipeline by inking a immunology-focused licensing deal with Sitryx Therapeutics worth more than $500m, while seperately securing an expanded US approval for its cancer therapy, Hernexeos (zongertinib). At the heart of Boehringer's deal with Sitryx is the latter's early-stage immunometabolic programme – which includes several oral small molecule inhibitor candidates targeting an undisclosed novel mechanism. Boehringer has touted these candidates as "potentially disease-modifying" options across certain inflammatory and autoimmune conditions.

Pharmaceutical Technology 27.2.2026
Read More

GLOBAL PHARMA NEWS

Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study

The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025. This competitive award – following a rigorous review process – is designed to support the company's phase 2 OCTOPOD-IV clinical trial. The study evaluates THEO-260, a novel therapeutic candidate developed to treat advanced ovarian cancer by killing both cancer cells and cancer-associated fibroblasts. The grant application was coordinated with several international partners, including The Institute of Cancer Research in London and the Clínica Universidad de Navarra. Two thirds of the funds will be received directly by Theolytics to advance the phase 2a expansion trial, which focuses on high-grade serous ovarian or endometrioid cancer.

Pharma Times 4.3.2026
Read More

Sanofi bets on Sino Biopharm's transplant drug in $1.5bn licensing deal

Sanofi has taken a chance on Sino Biopharmaceutical's first-in-class, anti-inflammatory and anti-fibrotic asset, rovadicitinib, through a licensing agreement worth up to $1.53bn. As part of this deal, Sanofi will pay $135m upfront for the global development, manufacturing and commercialisation rights to Sino's novel Janus kinase (JAK)/Rho-associated protein kinase (ROCK) inhibitor pill, rovadicitinib, which was developed by Sino's subsidiary, Chia Tai Tianqing Pharmaceutical Group. This agreement also sees Sanofi commit up to $1.39bn towards potential development, regulatory and sales-based milestone payments – taking the total value up to $1.53bn. The Hong Kong-based pharma is also eligible to receive up to double-digit tiered royalties on the drug's annual net sales.

Pharmaceutical Technology 4.3.2026
Read more

DRUG APPROVALS

European Commission Approves Exdensur – depemokimab

As an add-on maintenance treatment when it comes to critical asthma with type 2 inflammation that stands characterised by a blood eosinophil count within adults and also adolescents 12 years and above who happen to be inadequately controlled in spite of high dose inhaled corticosteroids – ICS plus another asthma controller. As an add-on therapy having intranasal corticosteroids when it comes to the treatment of adult patients having critical CRSwNP for whom the therapy with systemic corticosteroids and/or surgery does not offer the right disease control.

World Pharmacy Today 17.2.2026
Read More

GLOBAL PHARMA NEWS

MHRA approves imlunestrant tosylate as new breast cancer treatment

The Medicines and Healthcare products Regulatory Agency has approved imlunestrant tosylate, branded as Inluriyo, for adults with a specific type of breast cancer that is locally advanced or metastatic and has not responded, or has progressed, after at least one line of hormonal therapy. The treatment is indicated for cancers that are oestrogen receptor-positive and HER2-negative, and can only be used in patients with certain ESR1 gene mutations.

Pharma Times 25.2.2026
Read More

J&J announces Tecvayli-Darzalex combo approval from FDA for multiple myeloma

Johnson & Johnson (J&J) has announced the US Food and Drug Administration (FDA) approval for the combination of Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) for adults with relapsed or refractory multiple myeloma (r/r MM).This approval applies to patients who have undergone at least one prior treatment, including a proteasome inhibitor and an immunomodulatory agent. It aims to provide a new standard of care (SOC) and address disease relapse, which affects approximately 40% of patients.

Pharmaceutical Technology 4.3.2026
Read More

Sciwind secures China's NMPA approval for Ecnoglutide injection

Sciwind Biosciences has received China's National Medical Products Administration (NMPA) approval for its Ecnoglutide injection for chronic weight management. Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist intended for chronic weight management in Chinese adults with obesity or who are overweight. It is distinguished by its selective activation of the cAMP signalling pathway, reducing β-arrestin recruitment. This mechanism enables potent and sustained weight loss while supporting metabolic improvements and minimising the risk of chronic diseases.

Pharmaceutical Technology
Read More

ASSOCIATION ACTIVITIES

Circulars

BDMAI communicated industry related information to the members though the following circulars:

Sl. No.	Subject	Date of Issue
1	**Greening of MSMEs – Free Technical Assistance - An initiative of Telangana State Government under RAMP programme**	10.3.2026
2.	**BDMAI's proposal to organize a Pavilion at CPhI India 2026 – Request for expression of Interest to participate in the Pavilion**	6.3.2026
3.	**Technical Meet on ' Strategies for Sustainable Waste Water Treatment & ZLD Systems – March 12-13 2026**	6.3.2026
4.	**A Free Skill Development Course on Environmental Sustainability for MSMEs organized by ICC**	3.3.2026
5	**Industry Summit – Organized by Chemical Engineering Department of IIT, Hyderabad -28.02.2026**	23.2.2026

Representations

Some of our members approached us stating that Telangana Electricity Board officials are visiting the factories and asking for Occupation Certificates from the Local Bodies. If not submitted within 10 days, the connection will be changed from LT to HT or if already having HT connection, then change to higher category. Since the units do not have any Occupation Certificates from Local Bodies, requested BDMAI to make a representation to the electricity Board. A representation has been submitted to the Chairman, Electricity Regulatory Board, Telangana, requesting him to not insist for Occupation Certificate. Please click HERE to see the representation.

Events

BDMAI, in association with Association of Chloromethane Manufacturers organized a Seminar on Best Practices for Reducing Chloromethane Emissions and SOPs for Utilization of Hazardous Wastes in Bulk Drug Industry on 13.2.2026 . Three persons from Chloromethane Manufacturers Association and Mr. Vinod Kumar Babu from Re Sustainability have made the presentations. About 50 delegates from our Member companies participated in the event

Aragen Strengthens ESG Performance with Improved EcoVadis Rating in 2026

Aragen is pleased to announce a further advancement in its Environmental, Social and Governance (ESG) performance, achieving an improved EcoVadis score of 84 in the 2025 assessment, up from 82 in 2024. This milestone reflects the company's sustained focus on strengthening responsible business practices and advancing sustainability across its operations, earning Aragen the prestigious EcoVadis Gold Medal.

Key highlights from the 2025 EcoVadis assessment include:

- **Overall Score:** Increased from 82 in December 2024 to 84 in January 2026
- **Ethics:** Improved from 80 to 84, demonstrating enhanced governance frameworks and ethical business conduct
- **Sustainable Procurement:** Improved from 80 to 85, highlighting continued progress in responsible sourcing and supplier engagement

This growth reflects a structured and long-term commitment across all key sustainability pillars, including Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. The company acknowledges the collective efforts of its internal & external stakeholders and supply chain partners whose continued collaboration supports the advancement of Aragen's sustainability goals.

Cartridge Filters: The Silent Guardians of Pharmaceutical Manufacturing

Mr. Ritesh Karnik
Product Manager – Enviro Business
Thermax Limited

In pharmaceutical manufacturing, air quality is not merely a matter of housekeeping — it is a cornerstone of product integrity, operator safety, and regulatory compliance. Every stage of production, from tablet compression to coating and drying, generates dust. While often invisible to the naked eye, this dust can pose significant operational and safety challenges.

The pharmaceutical industry operates in highly controlled environments designed to minimize contamination and ensure the production of safe, sterile, and high-quality medicines. Critical parameters such as air quality and temperature are carefully regulated to prevent contamination from particles, microbes, and other pollutants.

Modern cartridge filter systems have become indispensable in managing these risks, offering pharmaceutical manufacturers a robust solution that aligns with stringent GMP norms and evolving global safety standards.

The Complex Nature of Pharmaceutical Dust

Pharmaceutical dust is far from uniform. Depending on the process, it may be fine and graded, hygroscopic, sticky, explosive, flammable, or even highly potent and toxic.

In tablet coating and fluid bed drying applications, for instance, dust is often sticky and hygroscopic, operating at temperatures of approximately 60°C. In tablet compression and mixing operations, dust may be free-flowing but still combustible, typically around 50°C.

The presence of combustible particulate matter introduces the risk of explosion, making dust management not just an environmental concern but a critical safety priority of the people working in the environment. In high-potency applications, containment becomes equally important, with solutions such as Bag-In/Bag-Out (BIBO) systems ensuring safe filter change and operator protection.

Process-Specific Filtration Strategies

Different pharmaceutical operations demand tailored dust collection strategies:

- **Tablet Coating & Fluid Bed Drying:**
  These applications often require cartridge collectors integrated with HEPA filtration to ensure high-efficiency particulate removal and compliance with cleanroom standards.

- **Tablet Compression:**

  Although the dust may be more free-flowing, explosion mitigation remains essential. Cartridge collectors with integrated ID fans and motors provide reliable airflow and dust capture.

- **Mixing & Sieving:**
  Even in relatively simpler operations, combustible dust characteristics necessitate well-designed cartridge filtration systems supported by safety devices.

Why Cartridge Filters Lead the Way

Cartridge filter technology offers distinct advantages for pharmaceutical environments:

- High filtration efficiency for fine particulates, MERV 15 ratings.
- Compact footprint suitable for space-constrained facilities
- High dust-holding capacity
- Plug & Play Design. Ease of maintenance
- Flexibility to adapt to varied process conditions

Understanding Deflagration Risk in Pharmaceutical Dust Handling

One of the most critical yet often underestimated hazards in pharmaceutical dust handling is deflagration — a rapid combustion phenomenon that occurs when combustible dust particles ignite and propagate flame at subsonic speeds through an enclosed space. In pharmaceutical environments where fine particulate matter is suspended in air, even minor ignition sources such as static discharge, mechanical sparks, or overheated surfaces can initiate combustion.

When ignition occurs inside a dust collector or process enclosure, the rapid pressure rise associated with deflagration can damage equipment, disrupt operations, and pose serious safety risks to personnel. For this reason, explosion protection must be integrated into system design from the outset. Typical mitigation measures include explosion venting, non-return valves (NRVs), isolation devices, and proper containment strategies to prevent flame propagation and secondary explosions.

Addressing deflagration risk is not only a safety requirement but also a critical component of regulatory compliance and responsible pharmaceutical manufacturing.

Looking Ahead

As pharmaceutical manufacturing advances toward higher potency compounds, continuous processing, and stricter compliance frameworks, dust control strategies must evolve in parallel. Cartridge filters stand out as a future-ready solution — combining operational efficiency, advanced safety features, and regulatory compliance in a single integrated system.
In an industry where precision defines success and safety underpins sustainability, cartridge filters quietly perform one of the most critical roles — ensuring clean air, protected operators, and uncompromised product quality.

Cartridge Filters

IMPORTS OF BULK DRUGS & INTERMEDIATES- APRIL - DECEMBER			
		Amounts in US $ Mn	
HS Code		2024-25	2025-26
17023010	Glucose liquid	0.41	0.93
17023020	Glucose solid	6.15	4.88
17023031	Dextrose,solid	5.45	3.98
17023039	Dextrose other than solid	6.86	10.54
17024039	Dextrose other than solid	1.13	1.34
29051410	Ethambutol, ethambutol hcl	26.54	21.93
29051420	Salbutamol sulphate	2.55	3.40
29054300	Mannitol	408.65	419.13
29054400	D-glucitol (sorbitol)	79.21	83.57
29071930	Thymol	0.63	0.84
29072200	Hydroquinone	251.62	246.45
29095010	Guaiacol	12.12	24.80
29124930	Heliotropin (piperonyl aldehyde)	0.12	0.00
29124940	3,4,5-trimethoxy-benzaldehyde	3.54	2.90
29154010	Monochloroacetic acide their salts and esters	19.24	11.72
29163120	Benzyl Benzoate	3.94	7.03
29163150	Benzocaine (ethylpara-amino benzoate)	0.19	0.91
29163400	Phenyl acetic acid	53.20	14.97
29171940	Ferrous fumerate	0.28	0.47
29171970	Ethoxy methylene malonate, diethyl malonate	149.02	105.74
29181120	Calcium lactate	2.84	2.38
29181320	Metroprolol tartrate	9.85	13.33
29181510	Potassium citrate	13.64	6.33
29181520	Sodium citrate	16.35	33.37
29181550	Ferric ammonium citrate	0.05	0.14
29181610	Calcium gluconate	67.63	56.65
29181620	Ferrous gluconate	0.00	0.23
29182110	Salicylic acid	208.50	152.82
29182120	Sodium salicylate	0.46	1.18
29182200	0-acetylsalicylic acid its salts and estrs	4.98	4.58
29182310	Methyl salicylate	9.37	5.92
29182320	Amino salicylate	0.00	0.33
29183030	Nalidixic acid	5.60	3.20
29199010	Glycerophosphoric acid	0.02	0.41
29199030	Iron glycerophosphate		
29214250	Herbicide		
29214600	amfetamine INN and its related apis	3.01	2.84
29215110	o phenylanediamine	123.76	86.36
29215120	M-phenylenediamine (m-di aminobenzene)	31.70	27.41
29215130	P-phenylenediamine	37.62	30.17
29215170	Para amini acetanalide		
29223100	Amfepra none(inn), methdone & mormethadonesalts	0.00	0.01
29224100	Lysine and its esters salts thereof	923.37	843.45
29224210	Glutamic acid	5.39	5.96
29224220	Monosodium glutamate (aginamoto)	451.80	460.09
29224400	Tilidine (INN) and its salts	0.00	0.01

29224910	Amino acetic acid (glycine)	196.69	133.45
29224920	N-methyl taurine	10.27	28.89
29225011	Para-amino-salicylic acid	3.47	0.14
29225013	Procaine hydrochloride	0.20	0.14
29225015	L-tyrosine(p-hydroxyphenylamine)	21.19	24.65
29225021	Frusemide	3.62	2.47
29225024	D0mperid0ne	0.00	1.07
29231000	Choline and its salts	20.31	17.53
29241100	Meprobamate (inn)	18.12	10.27
29242910	Acetanilide	0.00	0.03
29242960	Pyrazinamide(pyrazine carboxamide)	107.59	89.26
29242970	Pretilachlor	10.83	6.58
29242980	Paracetamol	17.68	31.65
29262000	1-Cyanoguanidine (dicyandiamide)	46.84	92.96
29263000	Fenproporex (inn) & its salts	570.67	419.92
29264000	Alpha-phenylacetoacetonitrile	0.00	9.45
29280010	Isoniazid	0.77	2.01
29309014	Industrial chemical	17.15	26.98
29309040	L-cystine (alpha-amino beta-thiopropionic acid)	0.00	89.47
29322010	Coumarin,mthylcoumrn & ehylcoumrn-lactones	141.32	0.00
29329300	3 -Carboxy(Para sulpho- phenyl)-5-Pyrazololne	7.63	5.74
29329600	Carbofuran	22.48	10.09
29331100	Phenazone (antipyrin) and its derivatives	0.00	25.36
29331910	3-carboxy (para sulpho-phenyl)-5- pyrazolone	9.81	12.38
29331920	1 (2,5- dichloro-4-sulpho phenyl)-3-methyl 5 Pyrazolone	1.41	5.88
29331930	3-methyl-1(4-sulpho-O-toluyl-5-pyrazolone)	1.24	3.30
29331940	Phenylmethylpyrazolone	0.02	0.02
29331950	1-phenyl-5-pyrazolone-3-carboxylic acid	7.19	4.94
29331960	1-(m-sulphophenyl)-3-pyrazolone	0.00	2.86
29331970	Analgin	2.75	4.33
29332910	Tinidazole	31.83	16.78
29332920	Metronidazole metronidiazole benzoate	0.13	1.51
29332930	Mebendazole	0.46	2.58
29332940	Dimetridazole	89.95	76.66
29334190	Levorphanol (inn) and its salts	1.18	0.61
29335200	Other Containing structure of quinoline or iso quinoline ring halogenated or non halogentated and not further fused	1.17	0.04
29335300	Malonylurea (barbituric acid) & its sals	0.00	0.29
29335400	Allobarbital and othr barbital compnds andits salts	33.44	43.20
29335500	Other derivatives of malonylurea (barbituric acid), salts thereof	1.90	0.44
29335910	Aminophylline(cordophylin)	1.66	8.19
29335920	Trimethoprim	0.01	0.00
29335940	Diethyl carbanazine citrate	6.04	1.44
29335950	1-Amino-4-Methyl piperazine	2.30	2.67
29339100	Bispiribac Sodium(Herbicide)	0.12	0.19
29339200	Alpra zolam, camazepam & other cmpnds of zepam, salts thereof	0.04	0.10

29349100	Azinphos-methyl (ISO)	19.44	13.94
29349200	Aminorex, brotizolam and other like cmpnds, salts thereof	0.00	0.00
29349910	Fentanyl	0.23	0.00
29349930	Chloro Thiophene-2-Carboxylic Acid	5.35	3.60
29349940	Morpholine	4.87	6.35
29349990	Pramoxine	0.04	0.06
29351000	Other Hetrocyclic compounds	0.00	0.07
29355090	Other Hetrocyclic compounds	5174.79	5132.36
29359011	N-Methylperfluorooctane sulphonamide	0.22	0.25
29359013	N-Ethylperfluorooctane sulphonamide	0.88	9.66
29359014	Flubendiamide(insecticide)	0.27	0.42
29359023	Other Perfluro Octane Suphonomides	5.69	5.60
29359024	Sulphamethoxazole	11.50	14.57
29359040	Sulphafurazole	0.00	0.00
29362100	Sulphadiazine	4.85	8.11
29362210	Sulphadimidine	0.00	4.05
29362290	Sulphacetamide	111.25	161.24
29362310	Sulphamethiazole	138.77	192.74
29362390	Sulfamide	26.33	20.46
29362400	Pyrazosuluron ethyl(Pesticide)	95.46	70.83
29362500	Vitamins a and their derivatives	40.32	21.58
29362610	Vitamin b1i(thiamine, aneurine) & its salt	73.37	90.41
29362690	Other vitamin b1i and its drivatives	112.87	101.01
29362700	Vitamin b2 (riboflavin, lactoplavin) and its salts	209.74	246.87
29362800	Other vitamin b2 and its derivatives	13.06	28.57
29362910	D-or dl-pantothenic acid (vitamin b3 or vitamin b5) and its derivatives	168.07	251.19
29362920	Vitamin b6 & its drvts	347.17	416.73
29362930	Vitamin b12 (cynocobalamin)	23.77	46.95
29362940	Other vitamin b12 and its derivatives	12.28	8.27
29362950	Vitamin c (ascorbic acid) & its drvtvs	18.38	14.62
29362990	Vitamin e and its derivatives	106.08	126.05
29369000	Folic acid (vitamin b9)	13.27	12.30
29371100	Nctnc acid & nctnmd(niacinamide/niacine	163.52	103.33
29371200	Vitamin k (menaphthonum b.p.)	9.49	22.06
29371900	Vitamin d	0.09	0.04
29372100	Vitamin h (bi0lin)	277.24	401.70
29372200	Other vitamins and thr drvtvs	342.30	493.04
29372300	Other, incl. natural concentrts	314.79	281.34
29372900	Somatotropin, its drvtvs& strctl analogves	223.02	209.87
29373100	Insulin and its salts	495.05	419.86
29375000	Other polypeptide hormones thr dtvtvs & strctl anlges	825.24	772.25
29379011	Cortisone,hydrocortisone,prednisone (dehy-drocortisone)and frednisolone and prdnsln(dehydrohydrocortisone)	0.00	0.01
29379019	Halgntd drvtvs of corti costeroidal	56.50	33.59
29379020	Oestrogens and progestogens	0.01	1.77
29379090	Othr steroidal hormons thr drvtvs and strctl	43.97	32.66

29381000	Epinethrine	95.85	72.00
29389010	Prostaglandins, tiromboxames& leukotrienesthr drvtvs & strclt anlges	441.15	454.00
29389020	Epinethrine	40.02	35.48
29389090	Other Catecholamine hormones, their derivatives and structural analogues	0.27	1.60
29391100	Amino acide Derivatives	0.86	0.24
29392010	Other Amino acide Derivatives	603.30	456.53
29392020	Rutoside (rutin) and its derivatives	254.42	32.17
29392030	Digoxin	5.23	7.98
29393000	Other glycosides ntrl/rprdcd by synthsis &thr slts ethrs drvtvs	0.04	2.94
29394100	Concentrates of poppy straw cmpnds of morphin, codeine, codone, the baine, salts thereof	3.45	3.63
29394300	Quinine alkaloids	157.58	266.14
29394400	Quinine hydrochloride	0.10	0.95
29394500	Quinine sulphate	0.01	0.02
29394900	Chl0r0quine ph0sphate	0.01	0.15
29395900	Caffeine and its salts	0.01	0.01
29396190	Ephedrine & its salts	5.18	6.59
29396210	Norephedrine and its salts	35.16	39.82
29396290	Levo Methaphatamine	1.21	1.25
29396300	Other ephedrives and thr salts	7.37	0.00
29396900	Other theophylline and aminophylline thr drvtvs, salts	0.37	0.00
29397200	Ergometrine	0.11	0.00
29397900	Other ergometrine salts	29.30	20.30
29398000	Ergotamine tartarate	2.55	0.01
29411010	Other alkaloids of rye ergot & drvtvs	42.31	80.69
29411020	Other of Vegitable origin	76.75	35.35
29411030	Non Vegetable Alkaloids	1718.26	928.29
29411040	Penicillins and its salts	3.08	4.65
29411050	Ampicilline & its salts	329.12	262.14
29411090	Amoxycilline & its salts	4.02	7.62
29412010	Cloxacilline & its salts	3168.92	2600.47
29412090	6 - apa	604.27	668.34
29413010	Other penicillins & thr drvtvs wth a pentcillianic acid strctr slts thereof	40.39	40.82
29413020	Streptomycins	18.40	18.53
29413090	Other streptomycine & drvtvs, salts	154.94	214.06
29414000	Doxycylime & its salts	77.59	87.82
29415000	Tetracycline/oxytetra - cycline & hr salts	180.87	184.73
29419011	Other tetracyclines & thr drvtvs slts	18.72	4.37
29419013	Chloramphenicol & its drvtvs slts thereof	1249.24	1400.13
29419014	Erthromycin & its drvtvs slts thereof	273.58	418.77
29419019	Rifampicin	99.39	299.75
29419020	3 Formyl Rifa S V(Rifaint)	0.76	0.00
29419030	Rifa S or Rifa S Sodium (Rifaint)	430.06	464.99
29419040	1-Amino-4-Methyl piperazine (Rifaint)	265.01	209.75
29419050	Other rifampicin and its salts	73.61	41.22

29419060	Cephalexin & its salts	69.99	52.50
29419090	Ciprofloxacine & its salts	22.14	22.84
29420011	Gentamycin & its salts	85.72	56.75
29420012	Neomycin	5862.57	6034.16
29420013	Norfloxacin & its salts	14.00	11.97
29420014	Other antibiotics	49.50	58.78
29420015	Other antibiotics	0.10	3.25
29420016	Cefadroxil	1.14	1.89
29420021	Ibuprofane	155.68	135.33
29420022	Nifedipine	208.29	160.27
29420023	Ranitidine	3.09	1.36
29420025	Danes salt of D(-) phenyl glycine	0.00	0.23
29420026	Timolo maleate, terbutoline sulphate, imipramine HCl, amitryptyline, Atenolol,Propanolol	0.00	0.37
29420027	Timolol maleate	0.29	0.00
29420031	Terbutoline sulphate	20.66	28.17
29420032	Imipramine hcl	10.38	8.66
29420033	Amitryptyline hcl	0.00	0.70
29420034	Cysteanune hcl	5.92	8.58
29420090	Atenolol, propronalol	0.09	0.00
96020030	Diloxanide furoate	2.03	3.19
Grand Total		33374.91	32123.02

EXPORTS OF BULK DRUGS & INTERMEDIATES APRIL - DECEMBER			
		Values in USD million	
HS Code	Description	2024-25	2025-26
17023010	Glucose liquid	40.44	41.24
17023020	Glucose solid	8.51	5.21
17023031	Dextrose,solid	12.67	11.84
17023039	Dextrose other than solid	0.23	0.30
17024039	Dextrose other than solid	0.08	0.05
29051410	Ethambutol, ethambutol hcl	5.52	3.38
29051420	Salbutamol sulphate	9.43	8.52
29054300	Mannitol	4.70	5.31
29054400	D-glucitol (sorbitol)	47.27	49.64
29071930	Thymol	6.78	5.16
29072200	Hydroquinone	8.21	9.12
29095010	Guaiacol	1.51	1.67
29124920	Heliotropin (piperonyl aldehyde)	0.00	0.00
29124940	3,4,5-trimethoxy-benzaldehyde	1.81	1.74
29154010	Monochloroacetic acide their salts and esters	11.05	8.63
29163120	Benzyl Benzoate	4.24	2.74
29163150	Benzocaine (ethylpara-amino benzoate)	1.47	2.34
29163400	Phenyl acetic acid	0.82	0.94
29171940	Ferrous fumerate	6.41	5.35
29171970	Ethoxy methylene malonate, diethyl malonate	0.00	0.17
29181120	Calcium lactate	0.19	0.10
29181320	Metroprolol tartrate	6.97	7.19
29181510	Potassium citrate	2.38	1.74
29181520	Sodium citrate	8.46	7.80
29181550	Ferric ammonium citrate	0.52	0.84
29181610	Calcium gluconate	5.69	3.92
29181620	Ferrous gluconate	0.86	0.44
29182110	Salicylic acid	2.08	2.79
29182120	Sodium salicylate	2.03	1.67
29182200	0-acetylsalicylic acid its salts and estrs	1.13	1.07
29182310	Methyl salicylate	6.15	6.29
29182320	Amino salicylate	0.36	0.46
29183030	Nalidixic acid	1.46	0.62
29199010	Glycerophosphoric acid	0.02	0.04
29199030	Iron glycerophosphate	0.04	0.01
29214250	Herbicide	0.00	14.53
29214600	amfetamine INN and its related apis	24.79	44.25
29215110	o phenylanediamine	0.61	0.86
29215120	M-phenylenediamine (m-di aminobenzene)	7.81	19.35
29215130	P-phenylenediamine	8.13	5.42
29215170	Para amini acetanalide	0.32	0.41
29223100	Amfepra none(inn), methdone & mormethadonesalts	0.38	0.73
29224100	Lysine and its esters salts thereof	1.55	2.56

29224210	Glutamic acid	0.15	0.18
29224220	Monosodium glutamate (aginamoto)	0.50	0.42
29224400	Tilidine (INN) and its salts	0.24	0.04
29224910	Amino acetic acid (glycine)	18.45	12.02
29224920	N-methyl taurine	0.03	0.04
29225011	Para-amino-salicylic acid	0.00	0.01
29225013	Procaine hydrochloride	0.05	0.09
29225015	L-tyrosine(p-hydroxyphenylamine)	0.01	0.00
29225021	Frusemide	14.18	12.92
29225024	D0mperid0ne	6.00	4.72
29231000	Choline and its salts	8.72	6.60
29241100	Meprobamate (inn)	2.61	0.35
29242910	Acetanilide	0.23	0.10
29242960	Pyrazinamide(pyrazine carboxamide)	4.06	2.64
29242970	Pretilachlor	0.04	12.29
29242980	Paracetamol	52.44	60.62
29262000	1-Cyanoguanidine (dicyandiamide)	0.00	0.10
29263000	Fenproporex (inn) & its salts	0.04	0.00
29264000	Alpha-phenylacetoacetonitrile	0.00	0.01
29280010	Isoniazid	0.85	0.76
29309014	Industrial chemical	0.00	3.58
29309040	L-cystine (alpha-amino beta-thiopropionic acid)	2.45	0.00
29322010	Coumarin,mthylcoumrn & ehylcoumrn-lactones	7.21	8.03
29329300	3 -Carboxy(Para sulpho- phenyl)-5-Pyrazololne	0.18	0.13
29329600	Carbofuran	0.22	0.34
29331100	Phenazone (antipyrin) and its derivatives	7.20	7.68
29331910	3-carboxy (para sulpho-phenyl)-5-pyrazolone	1.33	1.56
29331920	1 (2,5- dichloro-4-sulpho phenyl)-3-methyl 5 Pyrazolone	0.59	6.63
29331930	3-methyl-1(4-sulpho-O-toluyl-5-pyrazolone)	0.71	0.08
29331940	Phenylmethylpyrazolone	0.02	0.03
29331950	1-phenyl-5-pyrazolone-3-carboxylic acid	0.02	0.00
29331960	1-(m-sulphophenyl)-3-pyrazolone	0.04	0.08
29331970	Analgin	0.07	0.00
29332910	Tinidazole	2.47	3.10
29332920	Metronidazole metronidiazole benzoate	11.47	12.95
29332930	Mebendazole	4.08	5.55
29332940	Dimetridazole	5.28	3.71
29334100	Levorphanol (inn) and its salts	1.35	0.00
29334110	Levorphanol (inn) and its salts	0.00	0.66
29334190	Other Containing structure of quinoline or iso quinoline ring halogenated or non halogentated and not further fused	0.00	2.83
29335200	Malonylurea (barbituric acid) & its sals	0.50	0.79

29335300	Allobarbital and othr barbital compnds andits salts	3.65	2.04
29335400	Other derivatives of malonylurea (barbituric acid), salts thereof	1.05	1.25
29335910	Aminophylline(cordophylin)	0.53	0.46
29335920	Trimethoprim	9.46	9.31
29335930	Diethyl carbanazine citrate	0.79	0.19
29335940	1-Amino-4-Methyl piperazine	2.62	5.11
29335950	Bispiribac Sodium(Herbicide)	1.04	6.43
29339100	Alpra zolam, camazepam & other cmpnds of zepam, salts thereof	14.90	14.58
29339200	Azinphos-methyl (ISO)	0.11	0.20
29349100	Aminorex, brotizolam and other like cmpnds, salts thereof	4.72	9.23
29349200	Fentanyl	0.25	0.54
29349910	Chloro Thiophene-2-Carboxylic Acid	0.04	0.04
29349920	Morpholine	11.49	11.28
29349930	Pramoxine	0.04	6.46
29349940	Other Hetrocyclic compounds	0.00	26.15
29349990	Other Hetrocyclic compounds	438.42	506.00
29351000	N-Methylperfluorooctane sulphonamide	0.05	0.27
29352000	N-Ethylperfluorooctane sulphonamide	0.00	0.04
29355010	Flubendiamide(insecticide)	0.00	0.00
29355090	Other Perfluro Octane Suphonomides	1.79	1.50
29359011	Sulphamethoxazole	25.10	21.46
29359012	Sulphafurazole	0.01	0.00
29359013	Sulphadiazine	4.16	4.87
29359014	Sulphadimidine	0.05	0.02
29359015	Sulphacetamide	0.01	0.02
29359022	Sulphamethiazole	1.36	3.74
29359024	Sulfamide	0.00	0.00
29359040	Pyrazosuluron ethyl(Pesticide)	0.00	15.81
29362100	Vitamins a and their derivatives	16.63	15.29
29362210	Vitamin b1i(thiamine, aneurine) & its salt	7.39	8.67
29362290	Other vitamin b1i and its drivatives	14.74	11.20
29362310	Vitamin b2 (riboflavin, lactoplavin) and its salts	8.15	9.60
29362390	Other vitamin b2 and its derivatives	0.14	0.10
29362400	D-or dl-pantothenic acid (vitamin b3 or vitamin b5) and its derivatives	0.53	0.28
29362500	Vitamin b6 & its drvts	0.18	0.61
29362610	Vitamin b12 (cynocobalamin)	0.63	1.15
29362690	Other vitamin b12 and its derivatives	2.91	7.38
29362700	Vitamin c (ascorbic acid) & its drvtvs	8.15	9.19
29362800	Vitamin e and its derivatives	13.94	19.47
29362910	Folic acid (vitamin b9)	3.98	4.75
29362920	Nctnc acid & nctnmd(niacinamide/niacine	68.29	60.84
29362930	Vitamin k (menaphthonum b.p.)	4.93	6.14
29362940	Vitamin d	15.96	22.59

29362950	Vitamin h (bi0lin)	0.56	0.36
29362990	Other vitamins and thr drvtvs	13.88	14.44
29369000	Other, incl. natural concentrts	32.83	43.05
29371100	Somatotropin, its drvtvs& strctl analogves	0.21	0.07
29371200	Insulin and its salts	31.36	33.81
29371900	Other polypeptide hormones thr dtvtvs & strctl anlges	24.92	33.20
29372100	Cortisone,hydrocortisone,prednisone (dehy-drocortisone)and frednisolone and prdnsln(dehydrohydrocortisone)	9.35	9.53
29372200	Halgntd drvtvs of corti costeroidal	27.25	25.02
29372300	Oestrogens and progestogens	20.17	18.86
29372900	Othr steroidal hormons thr drvtvs and strctl anlges	85.95	90.41
29373100	Epinethrine	0.00	0.00
29375000	Prostaglandins, tiromboxames& leukotrienesthr drvtvs & strclt anlges	1.70	1.05
29379011	Epinethrine	0.01	0.00
29379019	Other Catecholamine hormones, their derivatives and structural analogues	0.85	0.43
29379020	Amino acide Derivatives	16.72	9.07
29379090	Other Amino acide Derivatives	19.44	17.89
29381000	Rutoside (rutin) and its derivatives	0.00	0.00
29389010	Digoxin	1.42	1.08
29389090	Other glycosides ntrl/rprdcd by synthsis &thr slts ethrs drvtvs	31.64	55.22
29391100	Concentrates of poppy straw cmpnds of morphin, codeine, codone, the baine, salts thereof	0.94	0.13
29392010	Quinine alkaloids	0.00	0.00
29392020	Quinine hydrochloride	1.71	3.38
29392030	Quinine sulphate	0.94	0.36
29392040	Chl0r0quine ph0sphate	1.22	1.23
29393000	Caffeine and its salts	43.72	53.94
29394100	Ephedrine & its salts	1.46	1.59
29394400	Norephedrine and its salts	1.40	2.27
29394500	Levo Methaphatamine	0.08	0.07
29394900	Other ephedrives and thr salts	1.90	1.36
29395900	Other theophylline and aminophylline thr drvtvs, salts	26.97	35.56
29396110	Ergometrine	0.00	0.00
29396190	Other ergometrine salts	0.00	0.00
29396210	Ergotamine tartarate	0.00	0.00
29396900	Other alkaloids of rye ergot & drvtvs	2.00	1.36
29397900	Other of Vegitable origin	89.71	121.98
29398000	Non Vegetable Alkaloids	12.27	10.20
29411010	Penicillins and its salts	0.02	0.14
29411020	Ampicilline & its salts	19.29	17.37
29411030	Amoxycilline & its salts	142.94	111.22
29411040	Cloxacilline & its salts	17.31	16.86

29411050	6 - apa	0.00	0.03
29411090	Other penicillins & thr drvtvs wth a pentcillianic acid strctr slts thereof	64.13	54.42
29412010	Streptomycins	0.01	0.03
29412090	Other streptomycine & drvtvs, salts	0.02	0.29
29413010	Doxycylime & its salts	0.54	0.97
29413020	Tetracycline/oxytetra - cycline & hr salts	1.58	0.77
29413090	Other tetracyclines & thr drvtvs slts	0.31	0.29
29414000	Chloramphenicol & its drvtvs slts thereof	1.91	1.65
29415000	Erthromycin & its drvtvs slts thereof	74.49	69.46
29419011	Rifampicin	6.94	10.69
29419012	3 Formyl Rifa S V(Rifaint)	0.00	0.00
29419013	Rifa S or Rifa S Sodium (Rifaint)	0.20	0.00
29419014	1-Amino-4-Methyl piperazine (Rifaint)	0.00	0.00
29419019	Other rifampicin and its salts	6.18	3.50
29419020	Cephalexin & its salts	7.24	4.90
29419030	Ciprofloxacine & its salts	16.22	16.66
29419040	Gentamycin & its salts	0.03	0.02
29419050	Neomycin	0.02	0.07
29419060	Norfloxacin & its salts	1.53	1.52
29419070	Other antibiotics	0.00	0.00
29419090	Other antibiotics	424.98	356.57
29420011	Cefadroxil	14.13	12.69
29420012	Ibuprofane	54.24	52.03
29420013	Nifedipine	1.21	2.11
29420014	Ranitidine	7.46	5.64
29420015	Danes salt of D(-) phenyl glycine	0.15	0.00
29420016	Timolo maleate, terbutoline sulphate, imipramine HCl, amitryptyline, Atenolol,Propanolol	0.08	0.02
29420021	Timolol maleate	3.61	3.07
29420022	Terbutoline sulphate	0.93	0.97
29420024	Imipramine hcl	0.45	0.63
29420025	Amitryptyline hcl	4.25	4.36
29420026	Cysteanune hcl	0.00	0.00
29420027	Atenolol, propronalol	8.15	8.43
29420031	Diloxanide furoate	2.36	2.47
29420032	Cimetidine	0.00	0.04
29420033	Oxyclozanide	4.57	6.72
29420034	Famotidine	9.66	10.25
29420090	Other diloxanide furoate, cimetidine, famotidine nes	795.84	796.92
96020030	Gelatin capsules,empty	64.87	59.10
Grand Total		3355.51	3502.12

BULK DRUG MANUFACTURERS ASSOCIATION OF INDIA

E-Marketing Portal for
Indian Bulk Drugs
www.bdmaiem.in
One Platform, Infinite Possibilities

A one-stop Platform to Showcase & Source APIs & Intermediates, Pallets, Impurities, CDMOs & CRAMS, Consultancy & Analytical Services, Vendors – Chemicals /Equipment / Packing and More!

Key Features:

- **Smart Search** – Find by product, company, CAS number, or HS code
- **Direct Enquiry System** – Contact suppliers instantly through the portal
- **Verified Indian Manufacturers** – Reliable, quality-focused companies
- **Vendor & Service Provider Listings** – Expand your network and reach buyers
- **Domestic & International Reach** - Promoting make in India Pharma globally

Join the Portal and Support BDMAI's mission to strengthen India's Bulk Drug Industry

Reach us at:
C-25, Industrial Estate, Sanathnagar, Hyderabad
www.bdmai.org; info@bdmai.org;ed@bdmai.org;
91-40-23706718/4804